The average one-year price target for Kymera Therapeutics (NasdaqGM:KYMR) has been revised to $77.71 / share. This is an increase of 11.33% from the prior estimate of $69.80 dated November 7, 2025.

Shares of Kymera Therapeutics, Inc. KYMR touched a 52-week high of $68.8 on Nov. 24. The stock is currently trading at $66.04. The rally is most likely due to investor optimism around Kymera’s lead ...

Kymera Therapeutics (KYMR) “announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares of common stock to be sold in this ...

Kymera Therapeutics recently reported progress across its immunology pipeline, including advancing IRAK4, STAT6, TYK2, and KT-621 programs, while also disclosing CEO share sales and responding to ...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is among the 14 best booming stocks to buy right now. Its shares have gained over 28% in the last three months, with Wall Street anticipating a further uptick ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

Kymera Therapeutics (NASDAQ:KYMR) underwent analysis by 25 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table encapsulates their recent ...

6 analysts have shared their evaluations of Kymera Therapeutics (NASDAQ:KYMR) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table provides a quick ...

WATERTOWN, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for ...

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the best performers on Monday. Kymera Therapeutics soared to a new ...